<p>泰瓦制药（Teva Pharmaceutical Industries，纽约证券交易所代码：TEVA - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票分析师将评级从 “强烈买入” 下调至 “买入”。</p>
<ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
<p>其他一些股票分析师最近也对 TEVA 发布了报告。加拿大丰业银行在 12 月 5 日（星期五）发布的报告中开始覆盖泰瓦制药的股票。他们给予该股票 “行业跑赢大盘” 的评级，并设定了 35.00 美元的目标价。美国银行在周二将泰瓦制药的目标价从 29.00 美元上调至 32.00 美元，并在研究报告中给予该股票 “买入” 评级。巴克莱在周二发布的研究报告中开始覆盖泰瓦制药的股票。他们为该公司设定了 “增持” 评级和 35.00 美元的目标价。瑞银集团在 9 月 24 日（星期三）将泰瓦制药的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对泰瓦制药的 “卖出（d-）” 评级。三位投资分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位则给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，共识目标价为 30.25 美元。</p>
<p><strong>查看我们最新的 TEVA 股票分析</strong></p>
<h2>泰瓦制药股价下跌 1.3%</h2>
<ul>
<li>泰瓦制药：为什么这家仿制药巨头现在是一个明智的买入选择</li>
</ul>
<p>泰瓦制药的股票在周五开盘价为 29.80 美元。该公司的 50 日简单移动平均为 23.43 美元，200 日简单移动平均为 19.60 美元。公司市值为 341.8 亿美元，市盈率为 49.67，市盈增长比率为 1.79，贝塔值为 0.67。泰瓦制药的 52 周低点为 12.47 美元，52 周高点为 30.20 美元。公司的速动比率为 0.82，流动比率为 1.11，债务与股本比率为 2.31。</p>
<h2>泰瓦制药的内部活动</h2>
<p>在相关消息中，董事罗伯托·米尼奥内于 11 月 6 日（星期四）出售了 20 万股公司的股票。该股票以平均价格 24.11 美元出售，总价值为 4,822,000.00 美元。交易后，该董事直接持有 495,000 股公司股票，价值约为 11,934,450 美元。此次交易使其持股减少了 28.78%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，内部人士马克·萨巴格于 12 月 9 日（星期二）出售了 216,892 股公司的股票。该股票以平均价格 28.73 美元出售，总价值为 6,231,307.16 美元。交易完成后，内部人士持有 52,828 股公司的股票，价值为 1,517,748.44 美元。此次交易使其持股减少了 80.41%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士已出售 532,360 股公司股票，价值为 14,364,929 美元。公司内部人士持有 0.49% 的股票。</p>
<h2>对泰瓦制药的对冲基金看法</h2>
<ul>
<li>2025 年准备上涨的两只仿制药股票</li>
</ul>
<p>机构投资者最近买入和卖出了该股票的股份。Cromwell Holdings LLC 在第三季度将其在泰瓦制药的持股增加了 40.3%。Cromwell Holdings LLC 现在拥有 2,191 股公司股票，价值 44,000 美元，此前在上个季度又购买了 629 股。Advisors Asset Management Inc.在第二季度购买了泰瓦制药的新股份，价值约为 41,000 美元。罗斯柴尔德投资公司在第三季度将其在泰瓦制药的持股增加了 97.0%。罗斯柴尔德投资公司现在拥有 2,738 股公司股票，价值 55,000 美元，此前在上个季度又收购了 1,348 股。JFS Wealth Advisors LLC 在第三季度将其在泰瓦制药的持股增加了 257.1%。JFS Wealth Advisors LLC 现在拥有 2,778 股公司股票，价值 56,000 美元，此前在上个季度又收购了 2,000 股。最后，LRI Investments LLC 在第三季度将其在泰瓦制药的持股增加了 246.0%。LRI Investments LLC 现在拥有 2,813 股公司股票，价值 57,000 美元，此前在上个季度又购买了 2,000 股。54.05% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>泰瓦制药公司简介</h2>
<p>（获取免费报告）</p>
<p>泰瓦制药有限公司在北美、欧洲、以色列及国际市场开发、生产、营销和分销仿制药、专科药物和生物制药产品。它提供各种剂型的仿制药，如片剂、胶囊、注射剂、吸入剂、液体、透皮贴剂、软膏和乳膏；无菌产品、激素、高效药物和细胞毒性物质的注射剂和固体剂型；以及带有医疗设备的仿制产品和组合产品。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过泰瓦制药</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>Synopsys 因 Ansys 整合推动增长而看涨</li>
<li>内部购买解析：投资者需要知道的事项</li>
<li>你能给自己最好的节日礼物是什么？好市多股票</li>
<li>投资优先股与普通股的区别</li>
<li>为什么 Zscaler 股票在经历 30% 的抛售后可能准备反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在梯瓦制药吗？</h2>
<p>在考虑梯瓦制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而梯瓦制药并不在名单上。</p>
<p>虽然梯瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

梯瓦制药

<p>华尔街禅在周六的一份报告中将梯瓦制药的评级从 “强力买入” 下调至 “买入”</p>

<p>Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Saturday.</p>
<div class="lb-trans"><p>泰瓦制药（Teva Pharmaceutical Industries，纽约证券交易所代码：TEVA - 获取免费报告）在周六向投资者发布的报告中，被华尔街 Zen 的股票分析师将评级从 “强烈买入” 下调至 “买入”。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 02/03 - 02/07</li>
</ul>
</div><p>A number of other equities analysts also recently issued reports on TEVA. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a &#34;sector outperform&#34; rating and a $35.00 price objective on the stock. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. UBS Group raised their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of &#34;Buy&#34; and a consensus price target of $30.25.</p>
<div class="lb-trans"><p>其他一些股票分析师最近也对 TEVA 发布了报告。加拿大丰业银行在 12 月 5 日（星期五）发布的报告中开始覆盖泰瓦制药的股票。他们给予该股票 “行业跑赢大盘” 的评级，并设定了 35.00 美元的目标价。美国银行在周二将泰瓦制药的目标价从 29.00 美元上调至 32.00 美元，并在研究报告中给予该股票 “买入” 评级。巴克莱在周二发布的研究报告中开始覆盖泰瓦制药的股票。他们为该公司设定了 “增持” 评级和 35.00 美元的目标价。瑞银集团在 9 月 24 日（星期三）将泰瓦制药的目标价从 23.00 美元上调至 26.00 美元，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对泰瓦制药的 “卖出（d-）” 评级。三位投资分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位则给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，共识目标价为 30.25 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TEVA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TEVA 股票分析</strong></p>
</div><h2>Teva Pharmaceutical Industries Trading Down 1.3%</h2>
<div class="lb-trans"><h2>泰瓦制药股价下跌 1.3%</h2>
</div><ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>泰瓦制药：为什么这家仿制药巨头现在是一个明智的买入选择</li>
</ul>
</div><p>Teva Pharmaceutical Industries stock opened at $29.80 on Friday. The business has a 50-day simple moving average of $23.43 and a two-hundred day simple moving average of $19.60. The company has a market cap of $34.18 billion, a P/E ratio of 49.67, a P/E/G ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $30.20. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.</p>
<div class="lb-trans"><p>泰瓦制药的股票在周五开盘价为 29.80 美元。该公司的 50 日简单移动平均为 23.43 美元，200 日简单移动平均为 19.60 美元。公司市值为 341.8 亿美元，市盈率为 49.67，市盈增长比率为 1.79，贝塔值为 0.67。泰瓦制药的 52 周低点为 12.47 美元，52 周高点为 30.20 美元。公司的速动比率为 0.82，流动比率为 1.11，债务与股本比率为 2.31。</p>
</div><h2>Insider Activity at Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>泰瓦制药的内部活动</h2>
</div><p>In related news, Director Roberto Mignone sold 200,000 shares of the business's stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company's stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the company's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company's stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 532,360 shares of company stock valued at $14,364,929. 0.49% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事罗伯托·米尼奥内于 11 月 6 日（星期四）出售了 20 万股公司的股票。该股票以平均价格 24.11 美元出售，总价值为 4,822,000.00 美元。交易后，该董事直接持有 495,000 股公司股票，价值约为 11,934,450 美元。此次交易使其持股减少了 28.78%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，内部人士马克·萨巴格于 12 月 9 日（星期二）出售了 216,892 股公司的股票。该股票以平均价格 28.73 美元出售，总价值为 6,231,307.16 美元。交易完成后，内部人士持有 52,828 股公司的股票，价值为 1,517,748.44 美元。此次交易使其持股减少了 80.41%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士已出售 532,360 股公司股票，价值为 14,364,929 美元。公司内部人士持有 0.49% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Teva Pharmaceutical Industries</h2>
<div class="lb-trans"><h2>对泰瓦制药的对冲基金看法</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年准备上涨的两只仿制药股票</li>
</ul>
</div><p>Institutional investors have recently bought and sold shares of the stock. Cromwell Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company's stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $41,000. Rothschild Investment LLC boosted its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company's stock valued at $55,000 after acquiring an additional 1,348 shares during the last quarter. JFS Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company's stock valued at $56,000 after acquiring an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC grew its holdings in shares of Teva Pharmaceutical Industries by 246.0% in the third quarter. LRI Investments LLC now owns 2,813 shares of the company's stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该股票的股份。Cromwell Holdings LLC 在第三季度将其在泰瓦制药的持股增加了 40.3%。Cromwell Holdings LLC 现在拥有 2,191 股公司股票，价值 44,000 美元，此前在上个季度又购买了 629 股。Advisors Asset Management Inc.在第二季度购买了泰瓦制药的新股份，价值约为 41,000 美元。罗斯柴尔德投资公司在第三季度将其在泰瓦制药的持股增加了 97.0%。罗斯柴尔德投资公司现在拥有 2,738 股公司股票，价值 55,000 美元，此前在上个季度又收购了 1,348 股。JFS Wealth Advisors LLC 在第三季度将其在泰瓦制药的持股增加了 257.1%。JFS Wealth Advisors LLC 现在拥有 2,778 股公司股票，价值 56,000 美元，此前在上个季度又收购了 2,000 股。最后，LRI Investments LLC 在第三季度将其在泰瓦制药的持股增加了 246.0%。LRI Investments LLC 现在拥有 2,813 股公司股票，价值 57,000 美元，此前在上个季度又购买了 2,000 股。54.05% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Teva Pharmaceutical Industries Company Profile</h2>
<div class="lb-trans"><h2>泰瓦制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.</p>
<div class="lb-trans"><p>泰瓦制药有限公司在北美、欧洲、以色列及国际市场开发、生产、营销和分销仿制药、专科药物和生物制药产品。它提供各种剂型的仿制药，如片剂、胶囊、注射剂、吸入剂、液体、透皮贴剂、软膏和乳膏；无菌产品、激素、高效药物和细胞毒性物质的注射剂和固体剂型；以及带有医疗设备的仿制产品和组合产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Teva Pharmaceutical Industries</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过泰瓦制药</li>
<li>股息捕捉策略：你需要知道的事项</li>
<li>Synopsys 因 Ansys 整合推动增长而看涨</li>
<li>内部购买解析：投资者需要知道的事项</li>
<li>你能给自己最好的节日礼物是什么？好市多股票</li>
<li>投资优先股与普通股的区别</li>
<li>为什么 Zscaler 股票在经历 30% 的抛售后可能准备反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRFVkE" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=TEVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在梯瓦制药吗？</h2>
</div><p>Before you consider Teva Pharmaceutical Industries, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑梯瓦制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而梯瓦制药并不在名单上。</p>
</div><p>While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然梯瓦制药目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

梯瓦制药（NYSE:TEVA）被华尔街 Zen 下调评级至买入